Publication Name	World Journal of Gastroenterology
Manuscript ID	62770
Country	Italy

Received	2021-01-26 15:04
Peer-Review Started	2021-01-26 15:13
To Make the First Decision
Return for Revision	2021-02-27 17:34
Revised	2021-03-09 16:19
Second Decision	2021-04-09 08:48
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-04-14 05:02
Articles in Press	2021-04-14 05:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-04-27 01:28
Publish the Manuscript Online	2021-04-29 02:12

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Evidence Review
Article Title	Pancreatic adenocarcinoma: Beyond first line, where are we?
Manuscript Source	Invited Manuscript
All Author List	Sara Cherri, Silvia Noventa and Alberto Zaniboni
ORCID	Author(s) ORCID Number Sara Cherri http://orcid.org/0000-0001-7062-8723 Silvia Noventa http://orcid.org/0000-0001-7423-6065 Alberto Zaniboni http://orcid.org/0000-0002-2140-7040
Funding Agency and Grant Number
Corresponding Author	Sara Cherri, MD, Medical Assistant, Department of Oncology, Fondazione Poliambulanza, Via Bissolati 57, Brescia 25124, Italy. sara.m.cherri@gmail.com
Key Words	Pancreatic adenocarcinoma; Second-line; Chemotherapy; Targeted therapy; Immunotherapy
Core Tip	The incidence of pancreatic ductal adenocarcinoma is increasing, with anticipation of a large impact on the population. Despite achieving a survival gain in first-line treatment in the last decade, to date, little has been achieved in second-line treatment. The molecular and genetic characteristics of this tumour represent a fundamental challenge for preclinical and clinical research. In this review, we illustrate current clinical practice in second-line treatment for advanced pancreatic adenocarcinoma and the research landscape of potential future prospects.
Publish Date	2021-04-29 02:12
Citation	Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol 2021; 27(17): 1847-1863
URL	https://www.wjgnet.com/1007-9327/full/v27/i17/1847.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i17.1847

Full Article (PDF)	WJG-27-1847.pdf
Full Article (Word)	WJG-27-1847.docx
Manuscript File	62770_Auto_Edited_LM.docx
Answering Reviewers	62770-Answering reviewers.pdf
Audio Core Tip	62770-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	62770-Conflict-of-interest statement.pdf
Copyright License Agreement	62770-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	62770-Language certificate.pdf
Peer-review Report	62770-Peer-review(s).pdf
Scientific Misconduct Check	62770-Scientific misconduct check.pdf
Scientific Editor Work List	62770-Scientific editor work list.pdf
CrossCheck Report	62770-CrossCheck report.pdf